[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-failure---nyha-ii---iv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-failure---nyha-ii---iv":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,46,69,93,126,158,184,210,235,261,286],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100598303","safety-and-effectiveness-of-left-bundle-branch-area-pacing-versus-conventional-cardiac-resynchronization-therapy-in-heart-failure-100598303",false,"NCT07069738","Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure","SYNCHRONICITY","Inclusion Criteria:\n\n1. Patient is age 18 years or above, or of legal age to give informed consent specific to state and national law\n2. Patient meets a guideline-based indication for a de novo CRT-D device\n3. Primary prevention indication for ICD therapy\n4. Ischemic or nonischemic cardiomyopathy with LVEF ≤ 35% within 6 months of enrollment (LVEF must be assessed after the subject has been on GDMT for a minimum of 3 months) using an appropriate method of assessment (i.e. Echo, MRI, etc)\n5. NYHA class II-IV despite maximally tolerated guideline directed medical therapy (GDMT)\\* for at least 3 months\n\n   \\*GDMT is defined as all four drug classes listed below for at least 3 months prior to enrollment unless the investigator provides justification (e.g., contraindicated, not tolerated or cost): Renin Angiotensin System Inhibitors (ACE, ARB, or ARNI) Evidence based betablockers (metoprolol succinate, carvedilol, bisoprolol) Mineralocorticoid antagonists SGLT2 Inhibitor medications\n6. Sinus rhythm with left bundle branch block (LBBB) defined as a QRS ≥ 140 ms in men and ≥ 130 ms in women with a predominantly negative deflection (QS or rS in lead V1 and mid QRS notching or slurring in at least two of the following leads: 1, aVL, V1, V2, V5, V6) within 3 months of enrollment\n7. Patient is willing to participate in LATITUDE™ NXT remote patient monitoring\n8. Patient is willing and capable of providing informed consent and participating in all testing associated with this investigation at an approved study site and at the protocol defined intervals (Note: Use of a legally authorized representative (LAR) is not allowed)\n9. Patient plans to remain geographically stable (not permanently moving to another location) and can commit to all study participation requirements (procedure, follow-up visits and testing requirements)\n\nExclusion Criteria:\n\n1. Persistent or permanent atrial fibrillation (AF) within 3 months prior to enrollment and documented in the medical record\n2. Frequent premature ventricular contractions (PVCs), atrial arrhythmias, and\u002For other causes of expected percentage of cardiac physiologic pacing (CPP) delivery below 95% at the time of enrollment\n3. Non-LBBB conduction abnormalities (including right bundle branch block (RBB) or intraventricular conduction delay (IVCD)) within 3 months prior to enrollment\n4. Complete, second degree or high degree atrioventricular (AV) block, that requires pacing at the time of enrollment\n5. Current or prior pacemaker, ICD or CRT implant (Also includes non-transvenous ICD technology and leadless pacemakers)\n6. Prior or planned mechanical or bioprosthetic tricuspid valve replacement\n7. Currently receiving or previously received positive inotrope therapy within 3 months prior to enrollment\n8. Unstable angina, acute myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention within 3 months prior to enrollment\n9. History of heart transplantation or left ventricular assist device (LVAD) implantation\n10. Less than 1 year of life expectancy at the time of enrollment\n11. Anticipated heart transplantation or LVAD implantation within 1 year of enrollment\n12. History of ventricular septal defect (VSD)\n13. Complex congenital heart disease\n14. Documented diagnosis of cardiac amyloidosis\n15. Known occlusion or other reason limiting central venous access for transvenous leads\n16. Women of childbearing potential who are, or plan to become, pregnant during the course of the study (assessment per investigator's discretion)\n17. Patient currently requiring dialysis\n18. Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)\n19. Patient with contrast dye allergy or unwilling\u002Fable to undergo pre-treatment with steroids and\u002For diphenhydramine\n20. Inability or refusal to comply with the follow-up schedule including subject living at such a distance from the investigational site that attending follow-up visits would be unusually difficult or burdensome\n21. Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies\u002Fregistries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.","ALL","18 Years",{"count":19,"type":20},850,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study will compare two different methods to pace the heart to treat heart failure including:\n\n1. The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardiac Resynchronization Therapy (CRT).\n2. The other method is using a lead implanted in the Left Bundle Branch Area (LBBA) of your heart. This method is called Left Bundle Branch Area Pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.",[26],"Heart Failure - NYHA II - IV",[28,29,30,31,32],"Heart Failure","Conduction System Pacing","Primary Prevention","Cardiac Resynchronization Therapy","Left Bundle Branch Area Pacing","RECRUITING","2026-07-01",{"date":36,"type":37},"2026-07-02","ACTUAL",{"date":39,"type":37},"2025-10-22",{"date":41,"type":20},"2029-11",{"name":43,"class":44},"Boston Scientific Corporation","INDUSTRY",35,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100643953","developmentandapplication-of-a-single-feature-recognition-model-for-heart-failure-based-onartificial-intelligence-optimization-algorithms-100643953","NCT07667452","DevelopmentandApplication of a Single Feature Recognition Model for Heart Failure Based onArtificial Intelligence Optimization Algorithms","Inclusion Criteria:\n\n* Age ≥ 18 years old;\n* Body mass index \\\u003C 35 kg\u002Fm2;\n* Diagnosed with heart failure: according to \"Chinese Guidelines for Diagnosis and Treatment of Heart Failure 2024\", \"2021 ESC Guidelines for Diagnosis and Treatment of Acute and Chronic Heart Failure\", and \"2022 AHA\u002FACC\u002FHFSA Guidelines for Management of Heart Failure\";\n* NYHA classification II - IV;\n* Able to fully understand the purpose and process of the trial and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* There are physical disabilities that prevent safe and thorough testing;\n* There are open wounds on the chest skin or the skin is allergic to the patches;\n* There is a large amount of pericardial effusion, pericardial tamponade, pleural friction rub, pneumothorax, and a large amount of pleural effusion, which may affect data collection;\n* The patient has severe comorbidities or unstable condition, which may interfere with data collection during the study period;\n* Other situations where the investigator believes the subject is not suitable to participate in this trial, such as those that may increase the risk of the trial, affect the subject's compliance with the protocol, or affect the subject's ability to complete the trial due to physical or psychological diseases or conditions.",{"count":53,"type":20},50,"OBSERVATIONAL","The goal of this observational study is to develop and validate a single-feature artificial intelligence algorithm based on data from a wearable ECG patch in patients with heart failure (HF). The main question it aims to answer is:\n\nDoes the algorithm, using synchronized ECG and accelerometer signals from the patch, achieve accurate detection of heart sounds (S1, S2, and in some patients S3, S4) compared to the Eko CORE500 digital stethoscope in patients with acute exacerbation of HF?\n\nParticipants with confirmed HF (NYHA class II-IV) will undergo two 2-minute sessions of simultaneous ECG patch and digital stethoscope recordings, followed by standard 12-lead ECG. Data will be used for algorithm training and validation, with the primary endpoint being the sensitivity and specificity of heart sound detection against the reference device.",[57,26],"Cardiac Sound","NOT_YET_RECRUITING","2026-06-23",{"date":61,"type":37},"2026-06-25",{"date":63,"type":20},"2026-06-01",{"date":65,"type":20},"2027-05-31",{"name":67,"class":68},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100566565","peripheral-drivers-of-heart-failure-progression---the-prospective-pedal-hf-study-100566565","NCT06656832","Peripheral Drivers of Heart Failure Progression - The Prospective PEDAL-HF Study","PEDAL-HF","Inclusion Criteria:\n\n* Patients admitted to the participating study centres with acute decompensated heart failure (ADHF), defined as clinical signs and\u002For symptoms of heart failure\n* objective structural cardiac abnormalitites according to the ESC criteria.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* pregnancy\n* any condition interfering with the informed consent process\n* patients placed in an institution by official or court order",{"count":77,"type":20},1000,[23],"PEDAL-HF is a registry-based randomized prospective multicenter study. The investigators plan to include 1000 patients who were recently admitted with acute decompensated heart failure at five tertiary heart clinics in Germany. For the randomised part, 750 patients will be randomized to care within a heart failure network or usual care. The primary endpoint of the randomized trial is change in NT-proBNP from baseline to 6 months of follow-up.\n\nAll patients (randomized or not) will be followed for two years.",[26],[82],"Heart Failure Network Care","2026-04-30",{"date":85,"type":37},"2026-05-06",{"date":87,"type":37},"2024-11-28",{"date":89,"type":20},"2028-12-31",{"name":91,"class":68},"University of Leipzig",1,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":92},"100613165","phase-4-urine-sodium-driven-diuretic-adjustment-strategy-in-acute-decompensated-heart-failure-100613165","NCT07263035","Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure","US-DASH","Inclusion Criteria:\n\n* The study will target adults 18 years of age or older admitted to Lakeland Regional Medical Center who:\n\n  * Have a primary diagnosis of acute decompensated heart failure, and\n  * Have at least one of the following signs of hypervolemia:\n\n    * Bilateral lower extremity pitting edema\n    * Jugular venous distension\n    * Hepatojugular reflex\n    * Crackles on pulmonary exam, or\n    * Chest x-ray demonstrating pulmonary edema or pleural effusions\n\nExclusion Criteria:\n\n* Exclusion criteria include:\n\n  * Admission to the intensive care unit\n  * Presence of ST-elevated myocardial infarction\n  * Presence of type 1 non-ST elevated myocardial infarction\n  * Dyspnea primarily due to non-cardiac cause as judged by the emergency medicine physician or admitting physician\n  * Use of supplemental oxygen totaling at least 3 L per minute or greater at baseline\n  * Anuria\n  * End-stage renal disease per KDIGO criteria\n  * Dialysis use",{"count":101,"type":20},600,[103],"PHASE4","The goal of this clinical trial is to learn if increasing the dose of diuretics to achieve a higher urine sodium target produces better clinical results when treating patients hospitalized with acute heart failure when compared to lower urine sodium target and standard of care.\n\nThe main questions it aims to answer are:\n\n1. Does targeting a higher urine sodium goal achieve greater natriuresis and diuresis?\n2. Does targeting a higher urine sodium goal reduce frequency of hospital readmissions?\n3. Does targeting a higher urine sodium goal reduce hospital length of stay?\n\nResearchers will compare natriuresis-guided arms with standard of care to see if targeting higher natriuresis goals improves significantly over current practice.\n\nParticipants will submit urine samples at routine intervals after being given diuretics to evaluate urine sodium concentration. If urine sodium is low then diuretic dose will be increased.",[28,26,106,107],"Heart Failure Acute","Acute Heart Failure (AHF)",[109,110,111,112,113,114,115,116],"Urine sodium","Diuretics","Lasix","heart failure","Acute CHF","acute HFrEF","Acute HFpEF","Natriuresis","2026-04-06",{"date":119,"type":37},"2026-04-09",{"date":121,"type":37},"2026-04-01",{"date":123,"type":20},"2027-09-01",{"name":125,"class":68},"Lakeland Regional Health Systems, Inc.",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":136,"studyType":54,"phases":4,"briefSummary":137,"conditions":138,"keywords":142,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":157},"100627382","ted-rogers-understanding-of-exacerbations-in-heart-failure-2-monitor-100627382","NCT07447908","Ted Rogers Understanding of Exacerbations in Heart Failure 2: Monitor","Ted Rogers Understanding of Exacerbations in Heart Failure 2 (TRUE-HF2): Observational Study","TRUE-HF 2","Inclusion Criteria:\n\n* broad age range (\\> 18 years of age)\n* NT-proBNP \\> 400 or 1000 if in AF\n* Within 3 months post discharge from HF hospitalization\u002F HF ED visit\u002F HF rapid clinic visit with intensification of diuretic therapy\n* NYHA functional class I-IV, heart failure with reduced and preserved ejection fraction\n* Literacy in English\n* Patient provided informed consent\n\nExclusion Criteria:\n\n* Unable to perform a CPET based on the standard protocol\n* End stage renal disease requiring dialysis\n* Living with LVAD\n* MRP deems patient unfit for the study\n* Post heart transplant",{"count":135,"type":20},360,"1 Year","Heart Failure (HF) is a complex disease associated with the highest burden of cost to the healthcare system. The cardiopulmonary exercise test (CPET) is instrumental in determining the prognosis of patients with HF. This multicentre study will validate whether aggregate biometric data from the Apple Watch combined with demographic, cardiac, and biomarker testing can improve our ability to predict heart failure outcomes among a diverse outpatient HF population.",[28,26,139,140,141],"Heart Failure Patients","Cardiopulmonary Exercise Test","Apple Watch",[141,143,28,144,145,146,147],"CPET","Artificial Intelligence","Wearable Technology","Wearable","Remote monitoring","2026-02-25",{"date":150,"type":37},"2026-03-04",{"date":152,"type":20},"2026-03-16",{"date":154,"type":20},"2029-09",{"name":156,"class":68},"University Health Network, Toronto",3,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":169,"conditions":170,"keywords":171,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":183},"100584117","remote-monitoring-of-cardiac-mechanics-in-heart-failure-patients-100584117","NCT06885164","Remote Monitoring of Cardiac Mechanics in Heart Failure Patients","Seismocardiographic Monitoring in Heart Failure","SeismicHeart","Inclusion Criteria:\n\n* NYHA Class II or higher\n* 18-90 years old\n\nExclusion Criteria:\n\n* Pregnancy\n* Drug addiction defined as the use of cannabis, opioids, or other drugs\n* Mechanical heart valves\n* In dialysis\n* Not possible to obtain clinical echocardiography of sufficient quality\n* Lack of ability to coorperate","90 Years",{"count":168,"type":20},200,"Heart failure is a severe heart disease, where the heart's ability to pump blood is unsatisfactory. The consequence is a high risk of hospitalization and death. Heart failure is treated with medicine which relieves symptoms and slows down the disease progression. This medical treatment needs routine adjustment, but in many cases, this adjustment is not done timely, which results in life treating conditions where the patients need acute hospitalization. Remote health monitoring of HF patients has the potential to ensure timely adjustment. However, only sensors placed inside the blood vessels of the lung, have been shown effective. The disadvantage is that the placement of the sensor requires surgery. This makes the method costly and poses a risk for the patient. The aim of the current project is to develop a small intelligent patch, which can measure the heart's function from the outside of the body. The method will be low-cost, simple to use and will not pose a risk to the patient.",[28,26],[112,172,173],"remote monitoring","cardiac mechanics","2026-01-15",{"date":176,"type":37},"2026-01-16",{"date":178,"type":37},"2025-06-11",{"date":180,"type":20},"2027-01-01",{"name":182,"class":68},"Aalborg University",2,{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":21,"phases":193,"briefSummary":194,"conditions":195,"keywords":196,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":205,"leadSponsor":207,"locationsCount":209},"100610071","evaluation-of-liver-stiffness-performance-by-fibroscan-to-detect-elevated-central-venous-pressure-cvp-100610071","NCT07222813","Evaluation of Liver Stiffness Performance, by FibroScan®, to Detect Elevated Central Venous Pressure (CVP)","Performance of Liver Stiffness Measurement (LSM) by FibroScan® for the Diagnosis of Elevated Central Venous Pressure (CVP)","Inclusion Criteria:\n\n1. Have read, understood, and signed the informed consent form (ICF)\n2. Be ≥18 years of age at the time of screening\n3. Have suspected or diagnosed acute or chronic HF and be scheduled to undergo right-sided cardiac catheterization\n\nExclusion Criteria:\n\n1. Inability to consent\n2. Chronic liver disease (self-reported alcohol use \\>14 drinks\u002Fweek in females and \\>21 drinks\u002Fweek in males), positive hepatitis C virus serology, positive hepatitis B surface antigen, autoimmune hepatitis, hemochromatosis, or cholestatic disease)\n3. BMI \\>40 kg\u002Fm2\n4. Fontan-type circulation\n5. Ascites\n6. Heart transplantation\n7. Pregnancy, breastfeeding, or intent to become pregnant during the study\n8. Intent to donate\u002Fbank or retrieve eggs (ova, oocytes) or donate sperm during the study",{"count":192,"type":20},149,[23],"This is a pivotal, global, prospective, cross-sectional, multicentric clinical investigation designed to explore a non-invasive, reliable alternative to invasive, catheter-based hemodynamic assessments, which are associated with procedural risks and limited applicability in certain participant populations.",[28,26],[197,198,199,200],"Fibroscan","Vibration Control Transient Elastography","Liver Stiffness Measurement","Guided VCTE","2025-10-28",{"date":203,"type":37},"2025-10-30",{"date":174,"type":20},{"date":206,"type":20},"2027-01-15",{"name":208,"class":44},"Echosens",7,{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":219,"conditions":220,"keywords":225,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":231,"leadSponsor":233,"locationsCount":4},"100608755","cardiovascular-performance-and-exercise-response-in-patients-with-persistent-or-permanent-atrial-fibrillation-and-heart-failure-pre-and-post-cardioversion-or-pace-and-ablate-100608755","NCT07205679","Cardiovascular Performance and Exercise Response in Patients With Persistent or Permanent Atrial Fibrillation and Heart Failure Pre and Post Cardioversion or Pace and Ablate","CPEX-CPA","Inclusion Criteria:\n\n1. Age ≥ 18\n2. Persistent or Permanent Atrial Fibrillation\n3. HF - NYHA class II-IVA despite guideline-direct medical therapy\n4. Rate controlled\n5. Able to perform stress test\n6. Scheduled for clinical P\\&A OR cardioversion\n\nExclusion Criteria:\n\n1. Creatinine \\>180 μmol\u002FL or eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2\n2. Significant valvular heart disease: Moderate to severe tricuspid regurgitation, mitral regurgitation, mitral stenosis, aortic regurgitation, aortic stenosis\n3. Patients who have had a TAVI, valvular surgery, or CABG within 3 months of enrolment\n4. Right ventricular systolic pressure \\>50mmHg\n5. Existing pacemaker\n6. In sinus rhythm\n7. Predictable vasovagal syncope to pain and sight of blood",{"count":218,"type":20},40,"Heart Failure (HF) and Atrial Fibrillation (AF) are two conditions that commonly occur together. Clinical guidelines consider a resting heart rate of 100-110 beats per minute (bpm) acceptable for patients with HF and AF while 72 bpm is considered the average in healthy populations. A higher resting heart rate indicates that the heart is working harder to meet bodily demands, and though it may be considered safe for patients with HF and AF to have a heart rate of 110 bpm, the investigators believe it is having a significant negative impact on patient quality of life and their ability to exercise. The current study will test exercise ability using a treadmill test before and after either a cardioversion, where the patient's heartbeat is reset using electric shocks, or a pace and ablate method, where the patient receives a pacemaker to regulate their heart rhythm and an ablation (intentional damaging) of the node that coordinates the beats within the heart. This will allow investigators to compare how the heart responds to exercise when the patient is on rate-control and anticoagulation medication therapy (before cardioversion or pace and ablate) and after the procedures. During exercise, the investigators will do a blood test that lets investigators know how efficiently the heart is working and record any symptoms experienced. The investigators will also collect information about the patient's quality of life. Using this information, the investigators hope to better understand whether the current standard of a resting heart rate of 100-110 bpm is ideal for patient quality of life.",[221,26,222,223,224],"Atrial Fibrillation (AF)","Pacemaker","Cardioversion","Ablation Therapy",[226],"Cardiopulmonary Exercise Testing","2025-10-01",{"date":229,"type":37},"2025-10-03",{"date":227,"type":20},{"date":232,"type":20},"2026-07",{"name":234,"class":68},"Habib Khan",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":21,"phases":245,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":92},"100595828","phase-1-low-dose-radiotherapy-for-heart-failure-100595828","NCT07037524","Low Dose Radiotherapy for Heart Failure","Prospective Pilot Single-center Study to Evaluate the Safety and Efficacy of Low-dose Radiotherapy in Patients With Heart Failure","RadioCardio","Inclusion Criteria\n\n* Age \\>18 years;\n* Clinical and laboratory diagnosis of chronic systolic HF grades II or III of the New York Heart Association with ejection fraction \\\u003C40%;\n* Refractoriness to standard clinical treatment; defined as the persistence of HF signs and symptoms despite optimized drug therapy.\n* Patient consent to participate in the study.\n* Agreement to adopt contraceptive practices\u002Fmethods until the end of the intervention for women of childbearing age.\n\nExclusion Criteria\n\n* Patients who have undergone any type of previous radiotherapy in the thoracic region;\n* Patients who have undergone heart transplants;\n* Contraindications for magnetic resonance imaging (MRI), such as the use of metal implants or prostheses.\n* Pregnant patients.",{"count":244,"type":20},10,[246,247],"PHASE1","PHASE2","The primary goals of this clinical trial are to evaluate the safety and efficacy of a low dose whole-heart radiotherapy with a single fraction in ten participants with advanced heart failure.",[26],[28,251],"Radiotherapy","2025-06-24",{"date":254,"type":37},"2025-06-25",{"date":256,"type":20},"2025-07-14",{"date":258,"type":20},"2030-09-30",{"name":260,"class":68},"Hospital do Coracao",{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":21,"phases":269,"briefSummary":270,"conditions":271,"keywords":272,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":4},"100596486","effects-of-a-20-minute-mindfulness-based-breathing-exercise-on-dyspnea-fatigue-and-sleep-quality-in-patients-with-heart-failure-100596486","NCT07046091","Effects of a 20-Minute Mindfulness-Based Breathing Exercise on Dyspnea, Fatigue, and Sleep Quality in Patients With Heart Failure","Inclusion Criteria\n\n* Over 18 years of age\n* Able to communicate effectively\n* No psychiatric disorders Exclusion Criteria\n* Patients with communication problems\n* Patients with psychiatric disorders",{"count":268,"type":20},72,[23],"Heart failure (HF) is a chronic condition that leads to incapacity. Despite significant progress in optimizing pharmacological treatment for HF patients, the personal and social burden of this disease is still characterized by debilitating symptoms and rehospitalizations. Today, many patients with heart failure use non-pharmacological methods for managing common symptoms. Due to the increased interest in non-pharmacological methods among individuals in society, it has become essential for healthcare professionals, including nurses as part of the healthcare team, to play a role in these methods to meet the health needs of the community.\n\nOne of the interventions nurses can offer for symptom management is mindfulness-based breathing exercises. In this mind-body-based practice, attention is focused on the breath, helping individuals develop awareness of their negative thoughts and emotions.\n\nThe study population will consist of patients admitted to the Cardiology Department of Firat University Hospital. The sample size was determined by a power analysis, with a 0.05 margin of error, a 0.95 confidence interval, and a 0.5 effect size, representing 80% of the population, resulting in 72 patients for both the experimental and control groups. Data collection tools for the study will include a Personal Information Form, the Dyspnea-12 Scale, the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale, and the Richard-Campbell Sleep Scale. SPSS (Statistical Programme for Social Sciences) software will be used to analyze the data obtained from the study.\n\nThe aim of this study is to determine the effects of a 20-minute mindfulness-based breathing exercise on dyspnea, fatigue, and sleep quality in patients with heart failure.",[28,26],[112,273,274,275,276],"mindfulness","dsypnea","fatigue","sleep quality","2025-06-23",{"date":279,"type":37},"2025-07-01",{"date":281,"type":20},"2025-08-15",{"date":283,"type":20},"2026-06-20",{"name":285,"class":68},"Firat University",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":157},"100566898","calibration-of-algorithm-for-detection-of-cardiac-decompensation-via-parametric-objects-cardcop-100566898","NCT06661161","Calibration of AlgoRithm for Detection of Cardiac Decompensation Via Parametric Objects (CARDCOP)","Calibration of AlgoRithm for Detection of Cardiac Decompensation Via Parametric Objects","CARDCOP","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patient diagnosed with chronic heart failure, confirmed by a cardiologist\u002Fcardio-geriatrician (regardless of the type and etiology of the disease), meeting at least one of the following two conditions:\n* Hospitalization in the past 12 months for a heart failure exacerbation.\n* NYHA class II to IV (New York Heart Association) at the time of inclusion, with elevated natriuretic peptide levels (BNP \\> 100 pg\u002FmL or NT-proBNP \\> 1000 pg\u002FmL).\n* French speaking patient\n* Patient equipped with a smartphone, computer, or tablet with internet\u002Fcellular access (of with the help of a caregiver)\n* Patient affiliated with a social security scheme\n\nExclusion Criteria:\n\n* Patient undergoing dialysis for renal failure\n* Patient who has received or is scheduled to receive a heart transplant or circulatory assistance within the next 12 months\n* Patient with a left ventricular ejection fraction ≥ 50% (for non-diastolic heart failure)\n* Obese patient with a body mass index ≥ 40 kg\u002Fm²\n* Patient with severe aortic stenosis who is contraindicated for surgery or TAVI\n* Patient with a life expectancy of \\< 1 year due to a condition other than heart failure (cancer, cirrhosis, respiratory failure, etc.)\n* Patient already benefiting from a telemonitoring device\n* Physical or psychological inability (dementia, schizophrenia, substance-related disorder) of the patient or caregiver to use the digital data collection device, as judged by the physician\n* Patient refusal to allow the transmission of the data necessary for monitoring the effective use of the device and obtaining individualized or national real-world usage results\n* Patient under guardianship, curatorship, or any other administrative or judicial measure restricting rights and freedoms\n* Patient unable to wear the watch for the duration of the study due to skin conditions",{"count":295,"type":20},640,"The goal of the study is to calibrate the algorithmic model of the TakeCoeur AI device to detect early heart failure decompensation in patients with heart failure, using physiological data (clinical) actively and passively collected through connected medical devices (watch, blood pressure monitor, and scale).",[26],"2024-10-24",{"date":300,"type":37},"2024-10-28",{"date":302,"type":20},"2024-11",{"date":304,"type":20},"2026-05",{"name":306,"class":68},"University Hospital, Brest"]